Form 4: Director Jorden Acquires 13,096 ALHC Restricted Stock Units

Alignment Healthcare Director Yon Jorden acquired 13,096 restricted stock units, vesting in one year, as part of their compensation.

Summary

• Director Yon Jorden of Alignment Healthcare, Inc. (ALHC) acquired 13,096 restricted stock units (RSUs).
• Each RSU represents a right to receive one share of the company's Common Stock.
• The RSUs were acquired on March 13, 2026, at a price of $0 per unit.
• These RSUs will vest on the one-year anniversary of the grant date, March 13, 2027, provided Jorden remains a member of the Board of Directors.
• Following this transaction, Jorden beneficially owns a total of 105,830 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued director commitment and a standard compensation practice that aligns interests with shareholders, without indicating any significant new strategic developments.

Positives

• Director Yon Jorden's acquisition of 13,096 restricted stock units demonstrates continued alignment of interests with shareholders.
• The grant of RSUs at a $0 price is a common form of equity compensation for directors, incentivizing long-term performance and retention.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports a routine equity grant.

Risks

• The vesting of the 13,096 restricted stock units is contingent upon Yon Jorden remaining a member of the Board of Directors until March 13, 2027.

Future Outlook

The vesting of the 13,096 restricted stock units on March 13, 2027, is contingent on Director Yon Jorden's continued service on the Board of Directors, indicating an expectation of continued tenure.

Management Comments

• No direct management comments or quotes are typically included in a Form 4 filing, which is a transactional report.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units, are a standard component of director compensation across the healthcare services industry. This practice aligns director incentives with long-term shareholder value, similar to compensation structures seen at peers like Humana or Centene, which also utilize equity to retain and motivate board members.

Comparison to Industry Standards

• Equity compensation for directors, often in the form of restricted stock units, is a widely adopted practice in the U.S. public company landscape, particularly within the healthcare sector.
• The grant of 13,096 RSUs to a director at a $0 acquisition price is consistent with typical non-cash equity awards designed to incentivize long-term commitment and performance.
• Vesting periods, such as the one-year anniversary of the grant date, are common for director RSU awards, aligning with annual board service cycles.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with long-term shareholder value, as the value of the RSUs is tied to the company's stock performance.

Next Steps

• The 13,096 restricted stock units are scheduled to vest on March 13, 2027, provided Yon Jorden remains a director.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and does not provide new information that would fundamentally alter the investment thesis for Alignment Healthcare, Inc. It reinforces director alignment but does not signal significant operational or financial changes warranting a change in investment recommendation.

Keywords

Alignment Healthcare, ALHC, Yon Jorden, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant